A consultation has been launched into proposed changes to the Association of British Pharmaceutical Industry (ABPI) Code of Practice. The ABPI Code regulates acceptable practice by pharmaceutical firms.
Key proposed updates:
- Adding clarifications to a number of rules to confirm that they also apply to digital engagement and advertisement
- Clarifying several passages related to journal advertising to clarify that this applies to print copies only (though with exemptions for risk minimisation material highlighting safety and risk issues)
- Clarifying practice on promotion of medicines under Conditional Licences and Early Access programmes
- Adding exemptions for material related to risk-minimisation so that this material is not limited by rules aimed at promotion
- Clarifications to allow limited non-promotional information-provision on products prior to approvals where this is important for service design and planning considerations
- Rules to allow companies to provide genetic testing services for the purposes of patient stratification
- Amendments for simplification, clarity, harmonisation with other codes, error correction, and removing redundant passages
The consultation is being launched by the Prescription Medicines Code of Practice Authority (PMCPA), the independent body responsible for overseeing the ABPI) Code of Practice, and closes 10th October.